These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 3504500)
1. Effect of encapsulation of mefenamic acid with cationic Eudragit E on its bioavailability and gastric ulcerogenic activity in rabbits. Ramadan EM; el-Helw A; el-Said Y J Microencapsul; 1987; 4(2):125-32. PubMed ID: 3504500 [TBL] [Abstract][Full Text] [Related]
2. Effect of particle size and film thickness on bioavailability and ulcerogenicity of encapsulated flufenamic acid. Foda A el-M ; el Said Y J Microencapsul; 1989; 6(2):227-32. PubMed ID: 2723967 [TBL] [Abstract][Full Text] [Related]
3. A new approach to encapsulating nonsteroidal anti-inflammatory drugs. I. Bioavailability and gastric ulcerogenic activity. Meshali MM; el-Dien EZ; Omar SA; Luzzi LA J Microencapsul; 1987; 4(2):133-40. PubMed ID: 3504501 [TBL] [Abstract][Full Text] [Related]
4. Polyacrylate resin microcapsules for taste masking of antibiotics. Friend DR J Microencapsul; 1992; 9(4):469-80. PubMed ID: 1403495 [TBL] [Abstract][Full Text] [Related]
5. Glyceride derivatives as potential prodrugs: synthesis, biological activity and kinetic studies of glyceride derivatives of mefenamic acid. Khan MS; Akhter M Pharmazie; 2005 Feb; 60(2):110-4. PubMed ID: 15739898 [TBL] [Abstract][Full Text] [Related]
6. Coated capsules for drug targeting to proximal and distal part of human intestine. Dvorácková K; Rabisková M; Gajdziok J; Vetchý D; Muselík J; Bernatoniene J; Bajerová M; Drottnerová P Acta Pol Pharm; 2010; 67(2):191-9. PubMed ID: 20369797 [TBL] [Abstract][Full Text] [Related]
7. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation. Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353 [TBL] [Abstract][Full Text] [Related]
8. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery. Akhgari A; Afrasiabi Garekani H; Sadeghi F; Azimaie M Int J Pharm; 2005 Nov; 305(1-2):22-30. PubMed ID: 16236475 [TBL] [Abstract][Full Text] [Related]
9. Development of nifedipine-loaded coated gelatin microcapsule as a long acting oral delivery. Li DX; Kim JO; Oh DH; Lee WS; Hong MJ; Kang JY; Choi JS; Woo JS; Yong CS; Choi HG Arch Pharm Res; 2009 Jan; 32(1):127-32. PubMed ID: 19183885 [TBL] [Abstract][Full Text] [Related]
10. The bioavailability and pharmacokinetics of mefenamic acid in alloxan-diabetic rabbits. Qamar S; Irfan N; Ahmad M; Jamshaid M; Muzaffar NA Tokai J Exp Clin Med; 1997 Oct; 22(4):163-6. PubMed ID: 9777006 [TBL] [Abstract][Full Text] [Related]
11. Combination of time-dependent and pH-dependent polymethacrylates as a single coating formulation for colonic delivery of indomethacin pellets. Akhgari A; Sadeghi F; Garekani HA Int J Pharm; 2006 Aug; 320(1-2):137-42. PubMed ID: 16782290 [TBL] [Abstract][Full Text] [Related]
12. Comparative dissolution studies for mefenamic acid-polyethylene glycol solid dispersion systems and tablets. Owusu-Ababio G; Ebube NK; Reams R; Habib M Pharm Dev Technol; 1998 Aug; 3(3):405-12. PubMed ID: 9742561 [TBL] [Abstract][Full Text] [Related]
13. Eudragit E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD). Leopold CS; Eikeler D J Drug Target; 1998; 6(2):85-94. PubMed ID: 9886233 [TBL] [Abstract][Full Text] [Related]
14. Sustained release spherical agglomerates of polymethacrylates containing mefenamic acid: in vitro release, micromeritic properties and histological studies. Ozyazici M; Sevgi F; Pekcetin C; Sarpas B; Sayin S Pharm Dev Technol; 2012; 17(4):483-893. PubMed ID: 21284557 [TBL] [Abstract][Full Text] [Related]
15. Colonic release and reduced intestinal tissue damage of coated tablets containing naproxen inclusion complex. Piao ZZ; Lee MK; Lee BJ Int J Pharm; 2008 Feb; 350(1-2):205-11. PubMed ID: 17928177 [TBL] [Abstract][Full Text] [Related]
16. Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles. Ubrich N; Schmidt C; Bodmeier R; Hoffman M; Maincent P Int J Pharm; 2005 Jan; 288(1):169-75. PubMed ID: 15607269 [TBL] [Abstract][Full Text] [Related]
17. The effect of the ratio of two acrylic polymers on the in vitro release kinetics of ketoprofen from pellets prepared by extrusion and spheronisation technique. Kibria G; Ul-Jalil R Pak J Pharm Sci; 2008 Apr; 21(2):92-7. PubMed ID: 18390436 [TBL] [Abstract][Full Text] [Related]
18. Development of an osmotically-driven pellet coated with acrylic copolymers (Eudragit® RS 30 D) for the sustained release of oxymatrine, a freely water soluble drug used to treat stress ulcers (I): in vitro and in vivo evaluation in rabbits. Piao H; Liu S; Piao H; Li X; Cui F Drug Dev Ind Pharm; 2013 Aug; 39(8):1230-7. PubMed ID: 22873131 [TBL] [Abstract][Full Text] [Related]
19. The influence of microencapsulation using Eudragit RS100 on the hydrolysis kinetics of acetylsalicylic acid. Vachon MG; Nairn JG J Microencapsul; 1997; 14(3):281-301. PubMed ID: 9147279 [TBL] [Abstract][Full Text] [Related]
20. Preparation and evaluation of Eudragit gels. I: Eudragit organogels containing drugs as rectal sustained-release preparations. Goto S; Kawata M; Suzuki T; Kim NS; Ito C J Pharm Sci; 1991 Oct; 80(10):958-61. PubMed ID: 1784005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]